Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Fingolimod Recommended for Approval
September 5, 2011
- Make the Premium for New Drug Development Permanent: FPMAJ, PhRMA, EFPIA Japan
September 5, 2011
- Increases in Social Security Spending to Be Covered by Cuts in Other Spending: FY2012 Budget
September 5, 2011
- US FDA Approves Vemurafenib for Melanoma; to Be Copromoted by Daiichi Sankyo
September 5, 2011
- Patent Office to Revise GL for Application of Patent Extension System
September 5, 2011
- Korosho to Apply for PIC/S Membership in Early FY2012: New CND Director Nakaigawa
September 5, 2011
- Almarl or Amaryl Should Be Renamed to Prevent Mistakes: MHLW
September 1, 2011
- Anticancer Drug Dispensed Instead of Norvasc Generic: MHLW Report
September 1, 2011
- Upgrading Quality Both in Facilities, Research for ICH-GCP: RDD Director Sahara
September 1, 2011
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…